Meeting
2023 ASCO Genitourinary Cancers Symposium
Characterization of anti-cancer immune response associated with immune-related adverse events in patients with kidney cancer.
Authors
Taigo Kato
Osaka University Graduate School of Medicine, Suita, Japan
Taigo Kato , Kazuma Kiyotani , Yu Ishizuya , Yoshiyuki Yamamoto , Koji Hatano , Atsunari Kawashima , Norio Nonomura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 711)
DOI
10.1200/JCO.2023.41.6_suppl.711
Abstract #
711
Poster Bd #
K6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2024 ASCO Annual Meeting
Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC.
First Author: Natalie J. Miller
Poster
2023 ASCO Breakthrough
Identification of intratumoral and peripheral T-cell receptor (TCR) repertoire features associated with acquired (Ar) and primary (Pr) resistance to immune checkpoint inhibitors (ICI).
First Author: Sofia Genta
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla